Kleeberg, U. R., & Schadendorf, D. (2004). Final results of the EORTC 18871/DKG 80-1 randomised phase III trial: RIFN-α2b versus rIFN-γ versus ISCADOR M® versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis. European journal of cancer, 40(3), . https://doi.org/10.1016/j.ejca.2003.07.004
Chicago-Zitierstil (17. Ausg.)Kleeberg, Ulrich R., und Dirk Schadendorf. "Final Results of the EORTC 18871/DKG 80-1 Randomised Phase III Trial: RIFN-α2b Versus RIFN-γ Versus ISCADOR M® Versus Observation After Surgery in Melanoma Patients with Either High-risk Primary (thickness >3 Mm) or Regional Lymph Node Metastasis." European Journal of Cancer 40, no. 3 (2004). https://doi.org/10.1016/j.ejca.2003.07.004.
MLA-Zitierstil (9. Ausg.)Kleeberg, Ulrich R., und Dirk Schadendorf. "Final Results of the EORTC 18871/DKG 80-1 Randomised Phase III Trial: RIFN-α2b Versus RIFN-γ Versus ISCADOR M® Versus Observation After Surgery in Melanoma Patients with Either High-risk Primary (thickness >3 Mm) or Regional Lymph Node Metastasis." European Journal of Cancer, vol. 40, no. 3, 2004, https://doi.org/10.1016/j.ejca.2003.07.004.